Results 1 to 10 of about 21,617 (174)

Idecabtagene vicleucel or ciltacabtagene autoleucel for relapsed or refractory multiple myeloma: An international multicenter study [PDF]

HemaSphere
Idecabtagene vicleucel (ide‐cel) and ciltacabtagene autoleucel (cilta‐cel) have revolutionized the treatment of relapsed/refractory multiple myeloma (RRMM), but direct comparisons are lacking.
Maximilian Merz, Anca‐Maria Albici, Bastian vonTresckow, Kristin Rathje, Roland Fenk, Tobias Holderried, Fabian Müller, Natalia Tovar, Aina Oliver‐Cáldes, Vladan Vucinic, Soraya Kharboutli, Ben‐Niklas Bärmann, Francis Ayuk, Uwe Platzbecker, Friedrich Stölzel, Nathalie Schub, Friederike Schmitz, David Fandrei, Patrick Born, Cyrus Khandanpour, Christine Hanoun, Keven Hörster, Marcel Teichert, Barbara Jeker, Michele Hoffmann, Nicolaus Kröger, Carlos Fernández de Larrea, Thomas Pabst, Nico Gagelmann   +28 more
doaj   +3 more sources

Efficacy of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma and prior central nervous system manifestation: A multicenter real‐world analysis [PDF]

HemaSphere
HemaSphere, Volume 9, Issue 8, August 2025.
Markus Maulhardt, Simon Call, Hristo Boyadzhiev, Anca Maria Albici, Keven Hörster, Amelie Boquoi, Snjezana Janjetovic, Anna Ossami Saidy, Marcel Teichert, Annamaria Brioli, Christian Schultze‐Florey, Florian Heidel, Philipp Schindler, Natalie Schub, Enver Aydilek, Matthias Stelljes, Michael Daskalakis, Carolin Krekeler, Justin Hasenkamp, Cyrus Khandanpour, Ulrike Bacher, Hans Christian Reinhardt, Georg Lenz, Friedrich Stölzel, Thomas Pabst, Bastian von Tresckow, Gerald Wulf, Philipp Berning, Evgenii Shumilov   +28 more
doaj   +3 more sources

Non-ICANS neurotoxicities CD19-directed CAR T-cell therapy and the emergence of movement and neurocognitive treatment-emergent adverse events: a case report [PDF]

Frontiers in Immunology
We report a 63-year-old male patient with diffuse large B-cell lymphoma (DLBCL) who developed delayed-onset neurotoxicity on day +22 following CD19-directed CAR T-cell therapy with axicabtagene ciloleucel (axi-cel), after an initial episode of CRS and ...
Torsten Schroeder, Guranda Chitadze, Justina Dargvainiene, Tjark Martens, Niklas Gebauer, Julia Frimmel, Monika Brüggemann, Thomas Valerius, Natalie Schub, Claudia D. Baldus, Christiane Pott, Frank Leypoldt, Frank Leypoldt, Klarissa Stürner, Friedrich Stölzel   +14 more
doaj   +2 more sources

Alterations in pathogen-specific cellular and humoral immunity associated with acute peripheral facial palsy of infectious origin [PDF]

Journal of Neuroinflammation, 2023
Background Peripheral facial palsy (PFP) is a common neurologic symptom which can be triggered by pathogens, autoimmunity, trauma, tumors, cholesteatoma or further local conditions disturbing the peripheral section of the nerve.
Leyla Mohammad, Mathias Fousse, Gentiana Wenzel, Marina Flotats Bastardas, Klaus Faßbender, Ulrich Dillmann, Bernhard Schick, Michael Zemlin, Barbara C. Gärtner, Urban Sester, David Schub, Tina Schmidt, Martina Sester   +12 more
doaj   +2 more sources

Time-resolved RNA signatures of CD4+ T cells in Parkinson’s disease [PDF]

Cell Death Discovery, 2023
Parkinson’s disease (PD) emerges as a complex, multifactorial disease. While there is increasing evidence that dysregulated T cells play a central role in PD pathogenesis, elucidation of the pathomechanical changes in related signaling is still in its ...
Caroline Diener, Martin Hart, Tim Kehl, Anouck Becker-Dorison, Tanja Tänzer, David Schub, Lena Krammes, Martina Sester, Andreas Keller, Marcus Unger, Barbara Walch-Rückheim, Hans-Peter Lenhof, Eckart Meese   +12 more
doaj   +2 more sources

The inactivated herpes zoster vaccine HZ/su induces a varicella zoster virus specific cellular and humoral immune response in patients on dialysisResearch in context [PDF]

EBioMedicine
Summary: Background: To evaluate the immunogenicity of the inactivated herpes-zoster vaccine HZ/su in patients at increased risk for VZV-reactivation, we analysed the quantity and quality of the vaccine-induced cellular and humoral immunity in patients ...
Franziska Hielscher, Tina Schmidt, Martin Enders, Sarah Leyking, Markus Gerhart, Kai van Bentum, Janine Mihm, David Schub, Urban Sester, Martina Sester   +9 more
doaj   +2 more sources

Comparative immunogenicity and reactogenicity of heterologous ChAdOx1-nCoV-19-priming and BNT162b2 or mRNA-1273-boosting with homologous COVID-19 vaccine regimens [PDF]

Nature Communications, 2022
Multiple formulations and technologies for vaccinating against SARS-CoV-2 exist but how the use of these in homologous or heterologous format impacts immunogenicity is far from clear.
Verena Klemis, Tina Schmidt, David Schub, Janine Mihm, Stefanie Marx, Amina Abu-Omar, Laura Ziegler, Franziska Hielscher, Candida Guckelmus, Rebecca Urschel, Stefan Wagenpfeil, Sophie Schneitler, Sören L. Becker, Barbara C. Gärtner, Urban Sester, Martina Sester   +15 more
doaj   +2 more sources

Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy [PDF]

Blood Cancer Journal
Despite the astonishing outcomes after chimeric antigen receptor (CAR) T-cell therapy for relapsed refractory multiple myeloma (RRMM), most patients eventually relapse.
Maximilian Merz, Danai Dima, Hamza Hashmi, Nausheen Ahmed, Friedrich Stölzel, Tobias A. W. Holderried, Roland Fenk, Fabian Müller, Natalia Tovar, Aina Oliver-Cáldes, Kristin Rathje, James A. Davis, David Fandrei, Vladan Vucinic, Soraya Kharboutli, Ben-Niklas Baermann, Francis Ayuk, Uwe Platzbecker, Anca-Maria Albici, Nathalie Schub, Friederike Schmitz, Leyla Shune, Jack Khouri, Faiz Anwer, Shahzad Raza, Joseph McGuirk, Zahra Mahmoudjafari, Kimberly Green, Cyrus Khandanpour, Marcel Teichert, Barbara Jeker, Michele Hoffmann, Nicolaus Kröger, Bastian von Tresckow, Carlos Fernández de Larrea, Thomas Pabst, Al-Ola Abdallah, Nico Gagelmann   +37 more
doaj   +2 more sources

P957: CARFILZOMIB, LENALIDOMIDE, DEXAMETHASONE FOLLOWED BY A SECOND AUTO-HCT IS AN EFFECTIVE STRATEGY IN FIRST RELAPSE MULTIPLE MYELOMA: A STUDY OF THE CHRONIC MALIGNANCIES WORKING PARTY OF EBMT [PDF]

HemaSphere, 2022
R. Tilmont, I. Yakoub-Agha, D.-J. Eikema, N. Zinger, M. Haenel, N. Schaap, C. Herrera Arroyo, C. Schuermans, W. Bethge, M. Engelhardt, J. Kuball, M. Michieli, N. Schub, K. M. O. Wilson, J. H. Bourhis, M. V. Mateos, N. Robin, E. Jost, N. Kröger, J. M. Moraleda, S. Sica, P. J. Hayden, M. Beksac, S. Schönland, S. Manier   +24 more
doaj   +2 more sources

Disease Note: First Report of Cladosporium ramotenellum Schub., Zalar, Crous & Braun, 2007 (Fungi: Dothideomycetes) as a Potential Contaminant of Date Palm Tissue Culture

Maǧallaẗ al-baṣraẗ al-ʻulūm al-zirāʻiyyaẗ, 2022
Cladosporium ramotenellum Schub., Zalar, Crous & Braun, 2007 an ascomycetes fungus, was isolated from cultured date palm tissues at callus induction stage in Date Palm Research Centre, University of Basrah.
Alaa N. Ahmed , Mohammed H. Abass
doaj   +3 more sources